Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Ironwood Pharmaceuticals

Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Mass., March 27, 2025 - Ironwood Pharmaceuticals, Inc. (the "Company") (Nasdaq: IRWD), a biotechnology

company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today

announced that it received a notification letter (the "Notice") on March 21, 2025 from the Listing Qualifications Department

of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Annual

Report on Form 10-K for the year ended December 31, 2024 (the "2024 Form 10-K") with the Securities and Exchange Commission

(the "SEC"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires

Nasdaq-listed companies to timely file all required periodic financial reports with the SEC.

The Notice from Nasdaq is standard practice in the event of a delayed

periodic financial report filing. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Under

Nasdaq rules, the Company has 60 calendar days from the date of the Notice, or until May 20, 2025, to submit to Nasdaq a plan to regain

compliance with the Rule. The Company plans to file its 2024 Form 10-K as soon as practicable and thereby expects to regain compliance

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a

biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases.

Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients

who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS (linaclotide), the

U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation

(CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon

our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases

and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is

headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on

Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking

statements, including statements about the Company's plan to file its 2024 Form 10-K as soon as practicable and thereby its expectations

for regaining compliance with the Rule. These forward-looking statements speak only as of the date of this press release, and Ironwood

undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties

that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties

include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical

development, manufacturing and formulation development of linaclotide, apraglutide, IW-3300, and our other product candidates; the risk

of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or

prevent our products' commercial success; the risk that healthcare reform and other governmental and private payor initiatives

may have an adverse effect upon or prevent our products' or product candidates' commercial success; the risk that apraglutide

will not be approved by the FDA or other regulatory agencies; the risk that clinical programs and studies, including for linaclotide

pediatric programs, apraglutide and IW-3300, may not progress or develop as anticipated, including that studies are delayed or discontinued

for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our ongoing

and completed nonclinical studies and clinical trials may not be replicated in later trials or further data analyses and earlier-stage

clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory

approval; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the

conditions that our products are approved to treat; the risk that we are unable to execute on our strategy to in-license externally developed

products or product candidates; the risk that we are unable to successfully partner with other companies to develop and commercialize

products or product candidates; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial

and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory

and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates,

that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not

able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize

our products as expected; the risk that the development of any of our linaclotide pediatric programs, apraglutide and/or IW-3300 is not

successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes

in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug

application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual

property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not

have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood's or AbbVie's

accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could

adversely affect our financial condition or restrict our future operations; and the risks listed under the heading "Risk Factors"

and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2023, and in our subsequent SEC filings.

Chief Financial Officer

Precision AQ (formerly Stern Investor Relations)